Published in J Virol on December 01, 1982
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J (1987) 6.26
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc Natl Acad Sci U S A (1983) 3.71
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Epstein-Barr virus with heterogeneous DNA disrupts latency. J Virol (1984) 3.51
Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes. Proc Natl Acad Sci U S A (1990) 3.29
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Spliced RNA from the IR1-U2 region of Epstein-Barr virus: presence of an open reading frame for a repetitive polypeptide. EMBO J (1984) 3.12
A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus. J Virol (1987) 3.10
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J (1998) 3.01
Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol (1989) 2.86
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 2.81
The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J Virol (1990) 2.75
EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol (1991) 2.70
Transformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H. J Virol (1985) 2.56
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc Natl Acad Sci U S A (1991) 2.54
B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J (1995) 2.51
The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol (1995) 2.36
BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol (1991) 2.28
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol (1992) 2.14
Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc Natl Acad Sci U S A (1988) 2.12
Identification of critical cis elements involved in mediating Epstein-Barr virus nuclear antigen 2-dependent activity of an enhancer located upstream of the viral BamHI C promoter. J Virol (1992) 2.09
The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J (1984) 2.00
B cell activation and the establishment of Epstein-Barr virus latency. J Exp Med (1988) 2.00
5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol (1989) 1.99
Epstein-Barr virus recombinants from overlapping cosmid fragments. J Virol (1993) 1.97
An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200). J Virol (1984) 1.76
P3HR-1 Epstein-Barr virus with heterogeneous DNA is an independent replicon maintained by cell-to-cell spread. J Virol (1985) 1.73
The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci U S A (1995) 1.68
oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol (1996) 1.67
Second-site homologous recombination in Epstein-Barr virus: insertion of type 1 EBNA 3 genes in place of type 2 has no effect on in vitro infection. J Virol (1992) 1.64
Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol (1996) 1.64
Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol (1995) 1.58
An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. J Virol (1994) 1.56
Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol (1992) 1.55
Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J (1996) 1.53
Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes. Proc Natl Acad Sci U S A (1988) 1.47
Sequences of the Epstein-Barr Virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA. J Virol (1987) 1.45
Palindromic structure and polypeptide expression of 36 kilobase pairs of heterogeneous Epstein-Barr virus (P3HR-1) DNA. J Virol (1986) 1.41
Identification and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epstein-Barr virus that is missing in its nonimmortalizing deletion mutant, P3HR-1. Proc Natl Acad Sci U S A (1985) 1.38
A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci U S A (1992) 1.35
Structure and role of the terminal repeats of Epstein-Barr virus in processing and packaging of virion DNA. J Virol (1995) 1.35
Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B. J Virol (1989) 1.34
Isolation and characterization of cDNA clones corresponding to transcripts from the BamHI H and F regions of the Epstein-Barr virus genome. J Virol (1987) 1.34
Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J Virol (1993) 1.31
Coinfection with multiple strains of the Epstein-Barr virus in human immunodeficiency virus-associated hairy leukoplakia. Proc Natl Acad Sci U S A (1992) 1.27
Epstein-Barr virus (EBV) SM protein induces and recruits cellular Sp110b to stabilize mRNAs and enhance EBV lytic gene expression. J Virol (2004) 1.27
The EBNA-2 arginine-glycine domain is critical but not essential for B-lymphocyte growth transformation; the rest of region 3 lacks essential interactive domains. J Virol (1994) 1.27
Epstein-Barr virus recombinants with specifically mutated BCRF1 genes. J Virol (1993) 1.26
Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J Virol (2000) 1.16
Molecular genetic analysis of Epstein-Barr virus Cp promoter function. J Virol (1996) 1.16
Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp). J Virol (1997) 1.16
The EBNA2-related resistance towards alpha interferon (IFN-alpha) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. Mol Cell Biol (1992) 1.15
Identification of the Epstein-Barr virus terminal protein gene products in latently infected lymphocytes. J Virol (1990) 1.14
B-cell lines immortalized with an Epstein-Barr virus mutant lacking the Cp EBNA2 enhancer are biased toward utilization of the oriP-proximal EBNA gene promoter Wp1. J Virol (1997) 1.12
Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol (2002) 1.08
Activated mouse Notch1 transactivates Epstein-Barr virus nuclear antigen 2-regulated viral promoters. J Virol (1999) 1.08
Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol (1995) 1.05
The switch between EBV latency and replication. Yale J Biol Med (1989) 1.05
Construction and use of cDNA clones for the mapping and identification of Epstein-Barr virus early P3HR-1 mRNAs. J Virol (1985) 1.04
Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia (2012) 1.02
Isolation of intertypic recombinants of Epstein-Barr virus from T-cell-immunocompromised individuals. J Virol (1996) 1.02
The Epstein-Barr virus EBNA-2 gene in oral hairy leukoplakia: strain variation, genetic recombination, and transcriptional expression. J Virol (1994) 1.00
Defective viral DNA in Epstein-Barr virus-associated oral hairy leukoplakia. J Virol (1990) 1.00
Marked variation in the size of genomic plasmids among members of a family of related Epstein-Barr viruses. Proc Natl Acad Sci U S A (1992) 0.98
Epstein-Barr Virus SM protein utilizes cellular splicing factor SRp20 to mediate alternative splicing. J Virol (2010) 0.96
Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. J Virol (2004) 0.93
Epstein-Barr virus nuclear protein 2A forms oligomers in vitro and in vivo through a region required for B-cell transformation. J Virol (1994) 0.92
Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A. J Virol (2007) 0.92
Epstein-Barr virus genetics: talking about the BAC generation. Herpesviridae (2010) 0.90
Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer (2016) 0.88
General and target-specific RNA binding properties of Epstein-Barr virus SM posttranscriptional regulatory protein. J Virol (2009) 0.87
Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220. J Virol (1988) 0.87
Autoantigenic proteins that bind recombinogenic sequences in Epstein-Barr virus and cellular DNA. Proc Natl Acad Sci U S A (1994) 0.87
Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain. J Virol (2001) 0.86
Negative autoregulation of Epstein-Barr virus (EBV) replicative gene expression by EBV SM protein. J Virol (2009) 0.86
An Epstein-Barr virus isolated from a lymphoblastoid cell line has a 16-kilobase-pair deletion which includes gp350 and the Epstein-Barr virus nuclear antigen 3A. J Virol (2001) 0.85
Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med (2004) 0.83
Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1. J Virol (2009) 0.82
EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells. J Virol (2006) 0.81
Amplification of Epstein-Barr virus (EBV) DNA by superinfection with a strain of EBV derived from nasopharyngeal carcinoma. J Virol (1988) 0.81
C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7. PLoS Pathog (2011) 0.81
T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice. J Virol (2014) 0.78
Points of recombination in Epstein-Barr virus (EBV) strain P3HR-1-derived heterogeneous DNA as indexes to EBV DNA recombinogenic events in vivo. J Virol (2008) 0.76
Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus. J Virol (2011) 0.75
Human neonatal lymphocytes immortalized after microinjection of Epstein-Barr virus DNA. J Virol (1987) 0.75
Heterogeneity of the Epstein-Barr virus major internal repeat reveals evolutionary mechanisms of EBV and a functional defect in the prototype EBV strain B95-8. J Virol (2017) 0.75
Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol (1975) 503.08
Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol (1977) 205.11
Construction and characterization of amplifiable multicopy DNA cloning vehicles derived from the P15A cryptic miniplasmid. J Bacteriol (1978) 75.38
Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A (1973) 12.70
Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature (1978) 9.25
Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science (1970) 7.60
Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells. J Biol Chem (1979) 6.31
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol (1980) 5.59
Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A (1974) 5.54
Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line. Proc Natl Acad Sci U S A (1981) 4.77
New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature (1982) 4.43
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol (1981) 4.38
DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell (1980) 4.14
Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res (1975) 3.02
Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs. J Virol (1980) 3.00
Molecular cloning of the complete Epstein-Barr virus genome as a set of overlapping restriction endonuclease fragments. Nucleic Acids Res (1981) 2.83
Heterogeneity of Epstein-Barr virus. III. Comparison of a transforming and a nontransforming virus by partial denaturation mapping of their DNAs. J Virol (1978) 2.78
Cloning and mapping of BamHi endonuclease fragments of DNA from the transforming B95-8 strain of Epstein-Barr virus. Proc Natl Acad Sci U S A (1980) 2.69
Cleavage of Epstein-Barr virus DNA by restriction endonucleases EcoRI, HindIII and BamI. Nucleic Acids Res (1978) 2.50
Genome of a mononucleosis Epstein-Barr virus contains DNA fragments previously regarded to be unique to Burkitt's lymphoma isolates. Cell (1981) 2.17
Organization of repeated regions within the Epstein-Barr virus DNA molecule. J Virol (1980) 2.12
NC37-R1 Epstein-Barr virus (EBV): a possible recombinant between intracellular NC37 viral DNA and superinfecting P3HR-1 EBV. Intervirology (1980) 1.92
Sites of sequence variability in Epstein-Barr virus DNA from different sources. Proc Natl Acad Sci U S A (1979) 1.78
Transforming activity of Epstein-Barr virus obtained by superinfection of Raji cells. Proc Natl Acad Sci U S A (1978) 1.72
Induction and biological characterization of the Epstein-Barr virus (EBV) carried by the Jijoye lymphoma line. Virology (1980) 1.55
Recovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV. Int J Cancer (1978) 1.49
Expression of Epstein-Barr viral early antigen in monolayer tissue cultures after transfection with viral DNA and DNA fragments. J Virol (1981) 1.48
Epstein-Barr virus and nonhuman primates: natural and experimental infection. Adv Cancer Res (1976) 1.37
Epstein-Barr viral DNA: infectivity for human placental cells. Science (1981) 1.33
Cloning overlapping DNA fragments from the B95-8 strain of Epstein-Barr virus reveals a site of homology to the internal repetition. J Virol (1981) 1.29
Mechanism of infection by Epstein-Barr virus. II. Comparison of viral DNA from HR-1 and superinfected Raji cells by restriction enzymes. Virology (1977) 1.23
Epstein-Barr virus DNA. X. Direct repeat within the internal direct repeat of Epstein-Barr virus DNA. J Virol (1981) 1.20
Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye. Int J Cancer (1980) 1.17
Interaction of the B95-8 and P3HR-1 substrains of Epstein-Barr virus (EBV) with peripheral human lymphocytes. Int J Cancer (1978) 0.90
Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A (1973) 12.70
Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proc Natl Acad Sci U S A (1972) 8.53
Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A (1985) 8.19
Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A (1981) 7.43
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med (1998) 6.84
A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1998) 6.76
Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A (1974) 5.54
Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J Virol (1997) 4.45
New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature (1982) 4.43
Stable expression in mouse cells of nuclear neoantigen after transfer of a 3.4-megadalton cloned fragment of Epstein-Barr virus DNA. Proc Natl Acad Sci U S A (1982) 4.23
Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol (1999) 4.20
Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol (1987) 4.12
Nucleic acid spot hybridization: rapid quantitative screening of lymphoid cell lines for Epstein-Barr viral DNA. Proc Natl Acad Sci U S A (1980) 4.10
Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med (1998) 3.75
Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells. Proc Natl Acad Sci U S A (1983) 3.71
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Epstein-Barr virus with heterogeneous DNA disrupts latency. J Virol (1984) 3.51
Kaposi's sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol (2000) 3.50
Prolonged oropharyngeal excretion of Epstein-Barr virus after infectious mononucleosis. N Engl J Med (1973) 3.33
Use of personal medical records for research purposes. BMJ (1994) 3.29
Establishment of cell lines from normal adult human blood leukocytes by exposure to Epstein-Barr virus and neutralization by human sera with Epstein-Barr virus antibody. Proc Soc Exp Biol Med (1971) 3.17
Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus. Proc Natl Acad Sci U S A (1973) 3.14
Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells. Proc Natl Acad Sci U S A (1987) 2.96
Efficiency of transformation of lymphocytes by Epstein-Barr virus. Virology (1977) 2.94
Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol (1989) 2.86
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol (1998) 2.84
Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. Nature (1990) 2.80
Polyadenylylated nuclear RNA encoded by Kaposi sarcoma-associated herpesvirus. Proc Natl Acad Sci U S A (1996) 2.76
Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat Genet (2001) 2.76
Two Epstein-Barr viral nuclear neoantigens distinguished by gene transfer, serology, and chromosome binding. Proc Natl Acad Sci U S A (1983) 2.68
Hantavirus pulmonary syndrome: the first 100 US cases. J Infect Dis (1996) 2.64
Infection and pathogenicity of chimeric simian-human immunodeficiency viruses in macaques: determinants of high virus loads and CD4 cell killing. J Infect Dis (1997) 2.60
Epstein-Barr viral antigen in single cell clones of two human leukocytic lines. J Virol (1970) 2.59
Major EB virus-specific cytoplasmic transcripts in a cellular clone of the HR-1 Burkitt lymphoma line during latency and after induction of viral replicative cycle by phorbol esters. Virology (1983) 2.54
Systemic and mucosal humoral responses to Helicobacter pylori in gastric cancer. Gut (1993) 2.47
Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ (2012) 2.33
Identification of Epstein-Barr nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2.9-kilobase-pair subfragment of the genome. Proc Natl Acad Sci U S A (1984) 2.32
Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus. Virology (1987) 2.32
Kaposi's sarcoma-associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein-Barr virus. J Virol (1999) 2.24
Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis (1996) 2.23
Biological properties and viral surface antigens of Burkitt lymphoma- and mononucleosis- derived strains of Epstein-Barr virus released from transformed marmoset cells. J Virol (1976) 2.22
Acute cardiac events temporally related to cocaine abuse. N Engl J Med (1986) 2.18
Genome of a mononucleosis Epstein-Barr virus contains DNA fragments previously regarded to be unique to Burkitt's lymphoma isolates. Cell (1981) 2.17
Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency. Proc Natl Acad Sci U S A (1988) 2.12
Comparison of the yield of infectious virus from clones of human and simian lymphoblastoid lines transformed by Epstein-Barr virus. J Exp Med (1973) 2.11
Recovery of Epstein-Barr virus from nonproducer neonatal human lymphoid cell transformants. Virology (1979) 2.09
Use of cloned probes to detect Epstein-Barr viral DNA in tissues of patients with neoplastic and lymphoproliferative diseases. J Infect Dis (1983) 1.99
Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis (1989) 1.99
Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses. J Exp Med (1977) 1.90
Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis (1985) 1.88
Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet (1998) 1.83
A randomized trial to evaluate the effectiveness of dietary advice by practice nurses in lowering diet-related coronary heart disease risk. Br J Gen Pract (1997) 1.81
Trypsinized placental cell cultures for the propagation of viruses and as "feeder layers". J Virol (1970) 1.77
Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev (1999) 1.76
Establishment of lines from normal human blood leukocytes by co-cultivation with a leukocyte line derived from a leukemic child. Proc Soc Exp Biol Med (1969) 1.76
P3HR-1 Epstein-Barr virus with heterogeneous DNA is an independent replicon maintained by cell-to-cell spread. J Virol (1985) 1.73
The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 1.72
Vaccinia virus replication and cytopathic effect in cultures in phytohemagglutinin-treated human peripheral blood leukocytes. J Virol (1968) 1.68
Role of the epstein-barr virus RTA protein in activation of distinct classes of viral lytic cycle genes. J Virol (1999) 1.66
Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol (1990) 1.62
Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. N Engl J Med (1980) 1.61
Analysis of the genomic sequence for the autosomal dominant polycystic kidney disease (PKD1) gene predicts the presence of a leucine-rich repeat. The American PKD1 Consortium (APKD1 Consortium). Hum Mol Genet (1995) 1.59
Expression in COS-1 cells of Epstein-Barr virus nuclear antigen from a complete gene and a deleted gene. J Virol (1984) 1.57
Resolution of invasive central nervous system aspergillosis in a transplant recipient. Bone Marrow Transplant (1997) 1.57
Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet (1974) 1.56
ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding specificities for sites in the Epstein-Barr virus BZLF1 promoter. J Virol (1991) 1.56
Transcriptional synergy by the Epstein-Barr virus transactivator ZEBRA. J Virol (1992) 1.55
The oncogenicity of Epstein-Barr virus. J Infect Dis (1974) 1.55
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia (2000) 1.54
Positron emission tomography in Alzheimer's disease. Neurology (1986) 1.52
Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. Lancet (1986) 1.51
Expression of Epstein-Barr viral early antigen in monolayer tissue cultures after transfection with viral DNA and DNA fragments. J Virol (1981) 1.48
Chronic Epstein-Barr virus infection associated with fever and interstitial pneumonitis. Clinical and serologic features and response to antiviral chemotherapy. Ann Intern Med (1986) 1.48
Structure of the bacteriophage lambda cohesive end site: location of the sites of terminase binding (cosB) and nicking (cosN). Gene (1983) 1.48